Unknown

Dataset Information

0

Potential drug-drug interaction and its determinants among patients with cancer receiving chemotherapy in oncology centres of Northwest Ethiopia: an institutional-based cross-sectional study.


ABSTRACT:

Objective

The study was conducted to assess potential drug-drug interactions (PDDIs) and its determinants among patients with cancer receiving chemotherapy.

Design and setting

An institutional-based cross-sectional study was used. This study was conducted from 1 June 2021 to 15 December 2021, in Northwest Ethiopia oncology centres.

Participants

All eligible patients with cancer received a combination of chemotherapy.

Outcomes

The prevalence and severity of PDDIs were evaluated using three drug interaction databases. Characteristics of participants were presented, arranged and summarised using descriptive statistics. The predictors and outcome variables were examined using logistic regression. The cut-off point was a p value of 0.05.

Results

Of 422 patients included in the study, 304 patients were exposed to at least one PDDI with a prevalence of 72.1% (95 % CI: 68% to 76%) using three drug interaction databases. There were varied reports of the severity of PDDI among databases, but the test agreement using the kappa index was 0.57 (95% CI: 0.52 to 0.62, p=0.0001) which is interpreted as a moderate agreement among three databases. Patients aged ≥50 years old had the risk to be exposed to PDDI by odds of 3.1 times (adjusted OR (AOR)=3.1, 95% CI (1.8 to 5.3); p=0.001) as compared with patients <50 years old. Similarly, patients with polypharmacy and comorbidity were more likely to be exposed to PDDI than their counterparts (AOR=2.4, 95% CI (1.4 to 4.1); p=0.002 and AOR=1.9, 95% CI (1.1 to 3.4); p=0.02, respectively).

Conclusion

The main finding of this study is the high prevalence of PDDI, signifying the need for strict patient monitoring for PDDIs among patients with cancer receiving chemotherapy. We suggest the use of at least three drug databases for quality screening. Patients with an age ≥50 years old, polypharmacy and comorbidity were significantly associated with PDDIs. The establishment of oncology clinical pharmacists and computerised reminder mechanisms for PDDIs through drug utilisation review is suggested.

SUBMITTER: Wondm SA 

PROVIDER: S-EPMC10728963 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Potential drug-drug interaction and its determinants among patients with cancer receiving chemotherapy in oncology centres of Northwest Ethiopia: an institutional-based cross-sectional study.

Wondm Samuel Agegnew SA   Tamene Fasil Bayafers FB   Gubae Kale K   Dagnew Samuel Berihun SB   Worku Asres Agegnehu AA   Belachew Eyayaw Ashete EA  

BMJ open 20231209 12


<h4>Objective</h4>The study was conducted to assess potential drug-drug interactions (PDDIs) and its determinants among patients with cancer receiving chemotherapy.<h4>Design and setting</h4>An institutional-based cross-sectional study was used. This study was conducted from 1 June 2021 to 15 December 2021, in Northwest Ethiopia oncology centres.<h4>Participants</h4>All eligible patients with cancer received a combination of chemotherapy.<h4>Outcomes</h4>The prevalence and severity of PDDIs were  ...[more]

Similar Datasets

| S-EPMC10860025 | biostudies-literature
| PRJNA1199600 | ENA
| PRJNA1199601 | ENA
| S-EPMC5926814 | biostudies-literature
| S-EPMC8297840 | biostudies-literature
| S-EPMC5931630 | biostudies-literature
| S-EPMC6836405 | biostudies-literature
| S-EPMC9639283 | biostudies-literature
| S-EPMC6663594 | biostudies-literature
| S-EPMC6625044 | biostudies-literature